YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Bloomberg reported on August 29 that hair-loss drug stocks are surging as Wall Street bets on a new pharmaceutical goldmine following the GLP-1 weight-loss boom. Shares of Veradermics, Incorporated (NYSE:MANE) have climbed nearly 500% sinc…
[FDA Headquarters] The Trump administration on Tuesday appointed the acting heads of the FDA units overseeing drugs, vaccines, and tobacco to permanent positions weeks after nominating White House advisor Heidi Overton as the agency's next…
AUSTIN, Texas, Sept. 3, 2026 /PRNewswire/ -- Equity Insider News Commentary - Pharmaceutical research is being rebuilt around artificial intelligence faster than the industry can absorb it. Arizton values the global AI in drug discovery ma…
[mRNA or messenger RNA. The concept of mRNA vaccine. Innovative methods to treat virus. 3d render] Krot Studio INVESTORS SHOULD KNOW: A major Phase 3 trial win from Moderna (MRNA [https://seekingalpha.com/symbol/MRNA]) and Merck (MRK [http…
[US 100 dollar bill folded into an up arrow on wooden table. Illustration of the concept of inflation, profit, earning and investment] Biotech stocks have reached their highest level since the height of the pandemic after Moderna (MRNA [ht…
Quick Read AMD's inaugural 13F puts $291 million into Sanmina, which posted 102% revenue growth after acquiring AMD's ZT Systems rack integration business. AMD holds $211 million in Nutanix stock and committed $150 million more to co-devel…
For Immediate Release Chicago, IL – August 18, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial m…
Artificial intelligence (AI) is poised to reshape pharmaceutical research by addressing some of the industry's most persistent challenges: lengthy timelines, high development costs and substantial clinical failure rates. Traditional drug d…
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Absci (ABSI) is back in focus after releasing early Phase 1 data for its lead antibody ABS-201 and securing a US$40 million…
Absci Corporation recently reported second-quarter 2026 results showing a net loss of US$33.21 million, wider than a year ago, while basic and diluted loss per share from continuing operations narrowed to US$0.21. Alongside these figures,…
Earnings Call Insights: Absci (ABSI) Q2 2026 MANAGEMENT VIEW * CEO Sean McClain said the company released “positive interim Phase I data” from the HEADLINE trial, adding “the data suggests the study drug was well tolerated with favorable s…
Key Points Interested in Absci Corporation? Here are five stocks we like better. ABS-201 showed encouraging early Phase 1 results: The antibody was well tolerated in interim data, with an estimated half-life of at least 65 days and potenti…
* Absci press release [https://seekingalpha.com/pr/20615676-absci-reports-business-updates-and-second-quarter-2026-financial-and-operating-results] (ABSI [https://seekingalpha.com/symbol/ABSI]): Q2 GAAP EPS of -$0.21 misses by $0.01. * Rev…
Absci Corporation Announced positive interim Phase 1 data from the HEADLINE™ trial of ABS-201 Completed $100 million underwritten offering, including $40 million strategic investment from Eli Lilly & Company Cash, cash equivalents, and mar…
Quick Read Tempus AI (TEM) hit five straight EPS beats with shares up 17%, as Twist Bioscience (TWST) logged 14 straight quarters of sequential revenue growth. Anthropic targets a September IPO with a healthcare AI pitch that could front-r…
[Heart Health Concept] Eoneren/E+ via Getty Images Wall Street investors are increasingly seeking refuge in high-performing equity plays as volatile healthcare markets continue to shift, forcing a critical evaluation of stock price velocit…
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Absci Corporation (ABSI) been one of those stocks this year? Let's take a closer look at the stock'…
Cathie Wood’s ARK Invest’s largest purchase during July 20-24 was Tesla (TSLA [https://seekingalpha.com/symbol/TSLA]), with the firm acquiring an additional $52.7M stake after a steep sell-off post weaker-than-expected Q2 earnings report.…
Issued on behalf of MindWalk Holdings Corp. (NASDAQ: HYFT) AUSTIN, Texas, July 24, 2026 /PRNewswire/ -- American News Group News Commentary - The race to bring artificial intelligence into drug discovery has become one of the most closely…
SpaceX (SPCX) investors are reeling after a brutal sell-off. The stock has comfortably slipped below its $135 IPO price, according to Yahoo Finance, facing concerns over Starship delays, an incredibly rich valuation, and a major post-earni…
We expect investors to focus on updates related to Viking Therapeutics' VKTX pipeline when it reports second-quarter 2026 earnings. In the last reported quarter, the company's earnings missed expectations by more than 44%. Since the compan…
Cathie Wood, CEO of Ark Investment Management, is known for buying high-growth stocks soon after they go public, especially when share prices pull back after an early rally. That's exactly what she's doing with SpaceX this week, adding mor…
Issued on behalf of MindWalk Holdings Corp. MindWalk Holdings Corp. (NASDAQ: HYFT) heads into its fourth-quarter and full-year results with fresh index inclusion, an expanded patent estate, and AI-designed programs aimed at two of medicine…
Cathie Wood, head of Ark Investment Management, is known for buying her favorite tech stocks during market pullbacks. That's exactly what she just did, adding shares of an AI stock after a sharp selloff. In 2025, the flagship Ark Innovatio…
Cathie Wood, head of Ark Investment Management, is known for betting on disruptive technology companies, and investors closely watch every move she makes. Sometimes, she'll even buy tech stocks on the way up — and that's what she just did,…
This article first appeared on GuruFocus. Cathie Wood's ARK Invest increased its exposure to artificial intelligence, digital assets and next-generation healthcare during the week of June 22 to 26, while reducing positions in streaming and…
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Absci Corporation stock is trading higher on Wednesday after the company reported positive interim Phase 1 results for its investigational…
Earlier this week, Absci Corporation reported encouraging interim Phase 1 data from its HEADLINE trial of ABS-201 for androgenetic alopecia, showing favorable safety, an estimated half-life of at least 65 days, and progression into a multi…
Absci ABSI shares surged 36% on Wednesday after the company reported positive interim data from the phase I portion of its ongoing phase I/IIa HEADLINE study evaluating ABS-201, an investigational PRLR antibody for androgenetic alopecia (A…
Absci Corporation (ABSI) shares soared 36% in the last trading session to close at $10.08. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 40.3% gain over the p…
(RTTNews) - "The market is a device for transferring money from the impatient to the patient." - Warren Buffett. Successful investing often comes down to patience, conviction, and the ability to stay the course through market fluctuations.…
Investing.com - U.S. stock index futures were mixed on Wednesday, with the S&P 500 and Nasdaq edging higher after a bruising two-day selloff in technology and semiconductor shares. Investors were also looking ahead to earnings from memory…
[Spot lit piggy bank] PM Images * Absci (ABSI [https://seekingalpha.com/symbol/ABSI]) is up ~20% in premarket trading Monday after announcing $100M in financing from Eli Lilly (LLY [https://seekingalpha.com/symbol/LLY]) as well as several…
Absci Corporation Eli Lilly & Company, Adage, BVF Partners, Columbia Threadneedle, Invus, Redmile, and large investment management firm invest $100 million in Absci Proceeds from offering to support continued advancement of ABS-201™ across…
Absci Corporation (NASDAQ:ABSI) is one of the 12 Best AI Drug Discovery Stocks Hedge Funds Are Loading Up On. On June 15, Guggenheim raised its price target on Absci Corporation (NASDAQ:ABSI) to $15 from $10. The analyst maintained a "Buy"…
Is ABSI a good stock to buy? We came across a bullish thesis on Absci Corporation on TradersPro's Substack. In this article, we will summarize the bulls' thesis on ABSI. Absci Corporation's share was trading at $7.27 as of June 15th.Ocugen…